Anika Therapeutics Inc.
As of Oct 22, 2026, Anika Therapeutics is in Stage 2, the uptrend phase, now in week 15 (since Jul 15, 2026). It closed at $21.09, 4.3% below its 52-week high and above its 200-day average, which is rising.
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care
Is ANIK early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ANIK among Drug Manufacturers - Specialty & Generic3rd of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
Anika Therapeutics: quick answers
What stage is Anika Therapeutics in?
As of Oct 22, 2026, Anika Therapeutics (ANIK) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 15, 2026 and is in week 15. What the four stages mean
Is Anika Therapeutics in an uptrend?
Yes. Anika Therapeutics is in a Stage 2 uptrend. It trades 34.2% above its 200-day average, which is rising.
How far is Anika Therapeutics from its 52-week high?
Anika Therapeutics closed at $21.09 on Oct 22, 2026, 4.3% below its 52-week high of $22.03. Its 52-week low is $9.13.
How has Anika Therapeutics performed over the past year?
As of Oct 22, 2026, Anika Therapeutics is up 115.6% over the past year and up 125.6% so far in 2026.
Which sector and industry is Anika Therapeutics in?
Anika Therapeutics is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.